Dermatology Times: June 9, 2025

12345678910111213141516
Across
  1. 4. Type of real-world data source supporting upadacitinib’s efficacy regardless of biologic history.
  2. 5. Symptom significantly improved by upadacitinib in patients with AD.
  3. 11. Treatment goal evaluated when personalizing AD therapeutic dosing.
  4. 12. Abbreviation for the Revolutionizing Atopic Dermatitis Conference held in Nashville.
  5. 13. Topical JAK inhibitor in development for chronic hand eczema.
  6. 14. Route of administration discussed in relation to steroid withdrawal and new JAK inhibitors.
  7. 15. Withdrawal from this class of drugs can mimic severe AD flares.
  8. 16. Abbreviation used for quality of life, a key outcome improved by new AD treatments.
Down
  1. 1. Therapy type explored for treating chronic itch beyond type 2 inhibition.
  2. 2. Key to distinguishing topical steroid withdrawal from AD flares.
  3. 3. JAK inhibitor shown effective in moderate to severe AD after dupilumab failure in real-world data.
  4. 6. Country where the CAN UpTIMISE study was conducted.
  5. 7. Common biologic that some patients fail to respond to in AD treatment.
  6. 8. Therapies considered when patients present with topical steroid withdrawal signs.
  7. 9. Therapeutic class discussed in context of dose personalization and AD treatment.
  8. 10. Term used to describe the advanced approach to AD treatment tailoring.